Suchergebnisse - "Diamond, Benjamin"

PubPharm (4)

1

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

enthalten in: Blood cancer journal | 2023

von Tan, C. | Derkach, A. | Nemirovsky, D. | +18

UpdateOf: Res Sq. 2023 Feb 24;:. - PMID 36865246

2

Tailored treatment to MRD response : A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2 ) in combination with lenalidomide and dexamethasone

enthalten in: American journal of hematology | 2021

von Korde, N. | Mastey, D. | Tavitian, E. | +25

3

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma : The MANHATTAN Nonrandomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Landgren, O. | Hultcrantz, M. | Diamond, B. | +40

4

Maintenance therapy and need for cessation studies in multiple myeloma : Focus on the future

enthalten in: Best practice & research. Clinical haematology | 2020

von Diamond, B. | Maclachlan, K. | Chung, D. | +2

1
[1]